

851702

6P1646/11

In re the application of Kenneth Rhodes, et al.

Case Docket No. MNI-070CP4

Serial No. 09/670,756

Filed: September 27, 2000

For: Potassium Channel Inertactors and Uses Therefor

COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Transmitted herewith for filing in connection with the above-identified application are the following:

Preliminary Amendment and Response to Restriction Requirement(10 pages);
 Request for One-Month Extension of Time (1 page) (in duplicate);
 Statement of Limited Recognition Under 37 CFR §10.9(b) for Maria C. Laccotripe; and
 Return mailroom postcard.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NO PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA
TOTAL	• 25	MINUS	** 54	0
INDEP.	• 12	MINUS	*** 3	9
<input checked="" type="checkbox"/> FIRST PRESENTATION OF MULTIPLE D.F.P. CLAIM				

SMALL ENTITY		OTHER THAN A SMALL ENTITY	
RATE	ADDT. FEE	RATE	ADDT. FEE
• 9	\$ 00	• 18	\$ 0.00
• 42	\$ 00	• 84	\$ 756.00
• 140	\$ 00	• 280	\$ 280.00
TOTAL ADDIT. FEE	\$ 0.00	TOTAL	\$ 1036.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

A check in the amount of _____ is enclosed for presentation of extra claims.
 A check in the amount of 110.00 is enclosed for One-Month Extension of Time.
 The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.
 Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
 Any patent application processing fees under 37 CFR 1.17.
 Please charge any additional fees or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed. Applicants request any extensions of time necessary to respond.

Express Mail - Standard Mail/Priority Mail/Commercial Mail

Postage Paid - May 15, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kenneth Rhodes

Signature

Larry Taylor

Please Print Name of Person Signing

By *Maria C. Laccotripe*
 Maria C. Laccotripe, Ph.D.
 Limited Recognition Under 37 CFR §10.9(b)
 28 State Street
 Boston, MA 02109
 (617) 227-7400
 Telecopier (617) 742-4214

H7G
JULY 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Kenneth Rhodes *et al.*

Serial No.: 09/670,756


Filed: September 27, 2000

For: POTASSIUM CHANNEL INTERACTORS AND
USES THEREFOR

Attorney Docket No.: MNI-070CP4

Group Art Unit: 1646

Examiner: Murphy, Joseph E.




Commissioner for Patents
Washington, D.C. 20231

"Express Mail" Mailing Label Number EL939 600 107 US

Date of Deposit May 15, 2002

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents.

Washington, DC 20231


Signature

Larry Taylor

Please Print Name of Person Signing

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Prior to examination of the above-identified application, please amend the application as follows.

In the claims:

Please cancel claims 1-7, 9, and 11-54 without prejudice, and amend claims 8 and 10 as follows:

8. (Amended) An isolated polypeptide comprising at least 12 contiguous amino acids of the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30.